1. Scrip
  2. >>COVID-19

Credit Where It Is Due: Pfizer’s COVID-19 Vaccine Smashes Launch Records As Expected

 
• By Jessica Merrill

Pfizer said it expects to generate $26bn in annual revenues from the COVID-19 vaccine BNT162b2 and is leveraging the platform to build out a durable business.

Record Breaking
Pfizer's forecast for BNT162b2 breaks industry's launch records • Source: Alamy

Pfizer Inc. launched the first COVID-19 vaccine BNT162b2, with partner BioNTech SE, and has succeeded in supplying the largest portion of the global market – and it is also reaping the financial rewards. Reporting first quarter sales and earnings 4 May that outperformed expectations overall, Pfizer raised its revenue forecast for BNT162b2 to $26bn in 2021 from a prior estimate of $15bn.

The raised forecast is likely still an underestimate, given the forecast accounts only for the 1.6 billion doses Pfizer has...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from COVID-19

Sanofi Bid For Second COPD Approval Hurt By Mixed Itepekimab Data

 
• By Kevin Grogan

One Phase III trial hits but a second study misses by a mile.

New Vaccine Framework Avoided Worst-Case Scenario, Analysts Say

 
• By Joseph Haas

The new US FDA vaccine guidelines introduced on 20 May might cause financial woes for Moderna, but overall vaccine makers should not be as impacted as feared.

Arcturus and CSL Take on Pfizer With Longer-Lasting COVID Vaccine

 
• By Kevin Grogan

Kostaive is the first self-amplifying mRNA COVID-19 vaccine to receive approval from the European Commission and could provide serious competition to Pfizer/BioNTech's Comirnaty and Moderna's Spikevax.

Under-Pressure Moderna Banks $590m To Speed Up Bird Flu Vaccine

 
• By Kevin Grogan

A week after a downbeat forecast at J.P. Morgan Healthcare Conference, the US mRNA specialist has pocketed another sizeable sum from the US Department of Health and Human Services to accelerate development of an H5N1 mRNA pandemic influenza vaccine.

More from Scrip

Nicox Plots US Submission After Another Phase III Glaucoma Win

 
• By Kevin Grogan

The France-headquartered firm’s eye drop has demonstrated efficacy in a second pivotal trial.

Rocket’s Warp Drive Back Online As FDA Lifts Danon Gene Therapy Hold

 
• By Alaric DeArment

The company took a prophylactic C3 inhibitor out of the immunomodulatory regimen used in its Phase II study of RP-A501, lowered the dose and adjusted its use of eculizumab.

Jazz Seeks Potential Expansion Of Epilepsy Franchise With Saniona Deal

 
• By Mandy Jackson

Deal Snapshot: Jazz, which sells Epidiolex for rare seizure disorders, will pay $42.5m up front to take over development of Saniona’s preclinical Kv7.2/Kv7.3 activator SAN2355 for epilepsy.